U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468513) titled 'Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.' on Jan. 27.
Brief Summary: A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (<30% activity)
Study Start Date: May 17, 2024
Study Type: INTERVENTIONAL
Condition:
Vivax Malaria
G6PD Deficiency
Intervention:
DRUG: Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus ...